Profile data is unavailable for this security.
About the company
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
- Revenue in USD (TTM)681.88m
- Net income in USD122.63m
- Incorporated2017
- Employees246.00
- LocationHarmony Biosciences Holdings Inc630 W Germantown Pike, Suite 215PLYMOUTH MEETING 19462United StatesUSA
- Phone+1 (484) 539-9800
- Fax+1 (302) 655-5049
- Websitehttps://www.harmonybiosciences.com/
More ▼
Mergers & acquisitions
| Acquired company | HRMY:NMQ since announced | Transaction value |
|---|---|---|
| Epygenix Therapeutics Inc | 13.61% | 680.00m |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | 555.46m | -8.77m | 1.16bn | 642.00 | -- | 2.86 | 22.45 | 2.09 | -0.4489 | -0.4489 | 28.67 | 20.44 | 0.5102 | 1.75 | 2.96 | 865,196.30 | -0.6514 | -2.83 | -0.7654 | -3.35 | 59.79 | 60.18 | -1.28 | -6.15 | 1.97 | 0.7018 | 0.5921 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Tilray Brands Inc | 812.04m | -212.62m | 1.17bn | 2.65k | -- | 0.3247 | -- | 1.43 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Innoviva Inc | 352.75m | 64.59m | 1.20bn | 112.00 | 27.84 | 1.79 | 11.48 | 3.40 | 0.6879 | 0.6879 | 4.78 | 10.68 | 0.2916 | 1.14 | 4.44 | 3,149,509.00 | 5.34 | 26.24 | 5.98 | 28.53 | 87.93 | -- | 18.31 | 76.84 | 1.64 | 1.93 | 0.4011 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Ocular Therapeutix Inc | 61.44m | -174.34m | 1.37bn | 267.00 | -- | 3.91 | -- | 22.28 | -1.30 | -1.30 | 0.4442 | 2.25 | 0.1883 | 2.48 | 2.28 | 230,116.10 | -53.42 | -46.70 | -59.98 | -54.18 | 90.59 | 89.36 | -283.75 | -228.65 | 12.94 | -27.52 | 0.1615 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Harrow Inc | 169.14m | -33.41m | 1.51bn | 315.00 | -- | 26.07 | -- | 8.90 | -0.9408 | -0.9408 | 4.76 | 1.63 | 0.5305 | 4.86 | 4.69 | 536,946.10 | -10.48 | -10.86 | -12.74 | -12.71 | 72.56 | 70.75 | -19.75 | -15.35 | 1.44 | -0.3529 | 0.7635 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Immunocore Holdings PLC - ADR | 296.55m | -47.11m | 1.62bn | 497.00 | -- | 4.29 | -- | 5.47 | -0.9494 | -0.9494 | 5.88 | 7.55 | 0.3593 | 0.541 | 5.68 | 596,681.90 | -5.71 | -27.55 | -7.45 | -36.82 | 99.38 | -- | -15.89 | -97.12 | 3.76 | -- | 0.5373 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Tarsus Pharmaceuticals Inc | 129.62m | -134.34m | 1.77bn | 244.00 | -- | 7.49 | -- | 13.67 | -3.76 | -3.76 | 3.58 | 6.22 | 0.4022 | 6.37 | 7.51 | 531,233.60 | -41.68 | -31.56 | -48.37 | -33.82 | 92.97 | -- | -103.64 | -242.59 | 5.38 | -- | 0.2319 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 1.87bn | 246.00 | 15.52 | 3.13 | 12.73 | 2.74 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.91bn | 3.00k | -- | 1.04 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 651.97m | 59.71m | 1.99bn | 652.00 | 33.82 | 1.98 | 13.95 | 3.06 | 1.07 | 1.07 | 11.71 | 18.24 | 0.4962 | 0.9689 | 4.54 | 999,957.10 | 4.54 | 4.95 | 5.83 | 6.41 | 89.04 | 88.61 | 9.16 | 12.84 | 1.98 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Ligand Pharmaceuticals Inc | 152.42m | 45.24m | 2.11bn | 58.00 | 45.97 | 2.49 | 26.10 | 13.83 | 2.43 | 2.43 | 8.25 | 44.84 | 0.1768 | 0.4689 | 4.34 | 2,627,966.00 | 5.25 | 12.32 | 5.37 | 12.99 | 93.52 | 81.65 | 29.68 | 80.32 | 11.81 | -- | 0.00003 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Amphastar Pharmaceuticals Inc | 723.55m | 157.72m | 2.13bn | 1.76k | 14.67 | 2.93 | 10.10 | 2.95 | 3.01 | 3.01 | 13.79 | 15.04 | 0.4684 | 2.83 | 5.60 | 410,873.90 | 10.28 | 9.42 | 11.88 | 11.56 | 52.98 | 47.83 | 21.95 | 15.23 | 2.61 | 9.42 | 0.4506 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Twist Bioscience Corp | 312.97m | -208.73m | 2.44bn | 923.00 | -- | 5.12 | -- | 7.80 | -3.60 | -3.60 | 5.39 | 8.03 | 0.4501 | 6.40 | 7.93 | 339,083.40 | -30.02 | -28.50 | -33.49 | -31.56 | 42.61 | 39.40 | -66.69 | -93.82 | 4.54 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Catalyst Pharmaceuticals Inc | 460.48m | 142.80m | 2.52bn | 167.00 | 18.04 | 3.82 | 13.99 | 5.48 | 1.17 | 1.17 | 3.78 | 5.54 | 0.777 | 4.34 | 8.66 | 2,757,377.00 | 24.10 | 25.42 | 27.94 | 29.81 | 86.32 | 85.63 | 31.01 | 30.87 | 4.92 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.68bn | -184.45m | 2.60bn | 7.70k | -- | -- | 32.33 | 0.9712 | -0.6835 | -0.6835 | 9.08 | -0.3016 | 0.75 | 2.96 | 3.73 | 348,106.50 | -4.10 | -4.80 | -5.45 | -5.93 | 35.34 | 34.76 | -5.46 | -9.00 | 0.8372 | 1.26 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Data as of Nov 21 2024. Currency figures normalised to Harmony Biosciences Holdings Inc's reporting currency: US Dollar USD
38.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 5.23m | 9.17% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.70m | 8.24% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.38m | 5.93% |
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 2.15m | 3.77% |
| Pacer Advisors, Inc.as of 30 Sep 2024 | 1.93m | 3.38% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.24m | 2.18% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 986.66k | 1.73% |
| American Century Investment Management, Inc.as of 30 Sep 2024 | 856.46k | 1.50% |
| LSV Asset Managementas of 30 Sep 2024 | 772.19k | 1.35% |
| Geode Capital Management LLCas of 30 Sep 2024 | 735.42k | 1.29% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
